Protalix BioTherapeutics (PLX) Operating Income (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Operating Income of $21.1 million for Q1 2026, up 610.16% year-over-year from $3.0 million in Q1 2025, and up 553.97% quarter-over-quarter from -$4.7 million in Q4 2025.
Protalix BioTherapeutics (PLX) Operating Income (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Operating Income history runs 17 years deep, the most recent figure standing at $21.1 million for Q1 2026.
- In Q1 2026, Operating Income rose 610.16% year-over-year to $21.1 million; the TTM figure through Mar 2026 stood at $19.8 million (up 327.64% YoY), while the FY2025 annual figure was -$5.5 million, down 240.41% from the prior year.
- Operating Income for Q1 2026 stood at $21.1 million, up from -$4.7 million in the prior quarter.
- The five-year high for Operating Income was $21.1 million in Q1 2026, with the low at -$5.6 million in Q4 2023.
- The 5-year median for Operating Income is -$2.4 million (2024), against an average of $1.0 million.
- The sharpest annual moves came in 2025 and 2026: Operating Income slumped 164.61% in 2025, then soared 610.16% in 2026.
- Protalix BioTherapeutics' Operating Income stood at -$2.5 million in 2022, then slumped by 125.05% to -$5.6 million in 2023, then soared by 228.39% to $7.2 million in 2024, then plunged by 164.61% to -$4.7 million in 2025, then soared by 553.97% to $21.1 million in 2026.
- Business Quant data shows PLX's Operating Income at $21.1 million in Q1 2026, -$4.7 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 4.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.67 Mn |
| Mar 31, 2026 | 21.15 Mn |
| Dec 31, 2025 | -4.66 Mn |
| Sep 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | -4.15 Mn |
| Dec 31, 2024 | 7.21 Mn |
| Sep 30, 2024 | 3.99 Mn |
| Jun 30, 2024 | -2.43 Mn |
| Mar 31, 2024 | -4.86 Mn |
| Dec 31, 2023 | -5.62 Mn |
| Sep 30, 2023 | -1.89 Mn |
| Jun 30, 2023 | 20.42 Mn |
| Mar 31, 2023 | -2.46 Mn |
| Dec 31, 2022 | -2.50 Mn |
| Sep 30, 2022 | -3.13 Mn |
| Jun 30, 2022 | -5.52 Mn |
| Mar 31, 2022 | -1.87 Mn |
| Dec 31, 2021 | -5.71 Mn |
| Sep 30, 2021 | -1.89 Mn |